Evidence map›Paper›PMID 36906694›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan.

Laura Vilar-Ribó, Judit Cabana-Domínguez, Lourdes Martorell, Josep Antoni Ramos-Quiroga, Sandra Sanchez-Roige, Abraham A Palmer, Elisabet Vilella, Marta Ribasés, Gerard Muntané, María Soler Artigas

Open access · hybridAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Laura Vilar-Ribó *Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8758-523X
Judit Cabana-Domínguez *Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4732-7284
Lourdes MartorellBiomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0003-4999-2197
Josep Antoni Ramos-QuirogaPsychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Sandra Sanchez-RoigeDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-6137-5699
Abraham A PalmerDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Elisabet VilellaBiomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0002-1887-5919
Marta RibasésPsychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1039-1116
Gerard Muntané *Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. muntaneg@peremata.com.ORCID http://orcid.org/0000-0003-1541-8365
María Soler Artigas *Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. maria.soler@vhir.org.ORCID http://orcid.org/0000-0002-3213-1107
Universitat Autònoma de Barcelona · ESInstituto de Salud Carlos III · ESUniversity of California San Diego · USUniversitat Pompeu Fabra · ES

Funding

A Framework for Translating Polygenic Findings Related to Alcohol Use Disorder Across SpeciesR01AA029688 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Hae Kyung Im, Abraham A Palmer · 2022 to 2026
$3.1M
Building Bridges to Allow Cross-species Translational genetics for the Study of AddictionDP1DA054394 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SANCHEZ ROIGE, SANDRA · 2021 to 2025
$2.4M
NIAAA NIH HHS R01 AA029688NIDA NIH HHS DP1 DA054394
6 · The paper itself

Abstract

There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = -0.36, P = 1.41e-16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e-06; Beta = -0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes.

Indexed as

Attention Deficit Disorder with HyperactivityGenome-Wide Association StudyHumansLongevityMendelian Randomization AnalysisPhenotype

Identifiers

PMID36906694
PMCPMC10209393
OpenAlexW4323926695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.